Delcath Systems Inc
DCTH
Market Cap$122.81M
Close$
$-3.93
179.4% downside
Current Fair Value
179.4% downsideOvervalued by 179.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $122.81 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.0 |
| Beta | 0.21 |
| Outstanding Shares | 24,562,692 |
| Avg 30 Day Volume | 288,357 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
ESG Score
No data
About Delcath Systems Inc
CEO: Jennifer Simpson Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is d...